

activities will be conducted throughout the United States.

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than May 19, 1997.

A. Federal Reserve Bank of Philadelphia (Michael E. Collins, Senior Vice President) 100 North 6th Street, Philadelphia, Pennsylvania 19105-1521;
1. *Susquehanna Bancshares, Inc.*, Lititz, Pennsylvania; to acquire 100 percent of the voting shares of Founders Bank, Bryn Mawr, Pennsylvania.

B. Federal Reserve Bank of St. Louis (Randall C. Sumner, Vice President) 411 Locust Street, St. Louis, Missouri 63102-2034:

1. *First Robinson Financial Corporation*, Robinson, Illinois; to become a bank holding company by acquiring 100 percent of the voting shares of First Robinson Savings Bank, National Association, Robinson, Illinois, the successor to the charter of First Robinsin Savings & Loan, F.A., Robinson, Illinois, which will convert from a mutual to a stock savings and loan association, and then to a national bank.

Board of Governors of the Federal Reserve System, April 21, 1997.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 97-10691 Filed 4-24-97; 8:45 am]

BILLING CODE 6210-01-F

FEDERAL RESERVE SYSTEM

Notice of Proposals to Engage in Permissible Nonbanking Activities or to Acquire Companies that are Engaged in Permissible Nonbanking Activities

The companies listed in this notice have given notice under section 4 of the Bank Holding Company Act (12 U.S.C. 1843) (BHC Act) and Regulation Y, (12 CFR Part 225) to engage *de novo*, or to acquire or control voting securities or assets of a company that engages either directly or through a subsidiary or other company, in a nonbanking activity that is listed in § 225.28 of Regulation Y (12 CFR 225.28) or that the Board has determined by Order to be closely related to banking and permissible for bank holding companies. Unless otherwise noted, these activities will be conducted throughout the United States.

Each notice is available for inspection at the Federal Reserve Bank indicated. Once the notice has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may

express their views in writing on the question whether the proposal complies with the standards of section 4 of the BHC Act.

Unless otherwise noted, comments regarding the applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than May 9, 1997.

A. Federal Reserve Bank of Minneapolis (Karen L. Grandstrand, Vice President) 250 Marquette Avenue, Minneapolis, Minnesota 55480-2171:

1. *Norwest Corporation*, Minneapolis, Minnesota; to acquire IMS Mortgage Company, Cedar Rapids, Iowa, and thereby engage in residential mortgage lending activities, pursuant to § 225.28(b)(1) of the Board's Regulation Y. The co-venturers will be Norwest Ventures, Inc., Des Moines, Iowa, and East Brook Corporation of Iowa, d/b/a/ Skogman Realty, Cedar Rapids, Iowa.

Board of Governors of the Federal Reserve System, April 21, 1997.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 97-10690 Filed 4-24-97; 8:45 am]

BILLING CODE 6210-01-F

FEDERAL RESERVE SYSTEM

Sunshine Act Meeting

AGENCY HOLDING THE MEETING: Board of Governors of the Federal Reserve System.

FEDERAL REGISTER CITATION OF PREVIOUS ANNOUNCEMENT: 62 FR 18629-30, April 16, 1997.

PREVIOUSLY ANNOUNCED TIME AND DATE OF THE MEETING: 11:00 a.m., Monday, April 21, 1997.

CHANGES IN THE MEETING: Addition of the following closed items to the meeting: (1) Proposed amendments to the Voluntary Guide to Conduct for Senior Federal Reserve System Officials; and (2) Status Report of the Committee on the Federal Reserve in the Payments Mechanism (Alternative Roles for the Federal Reserve in the Retail Payments System).

CONTACT PERSON FOR MORE INFORMATION: Mr. Joseph R. Coyne, Assistant to the Board; (202) 452-3204.

Dated: April 22, 1997.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 97-10824 Filed 4-23-97; 10:30 am]

BILLING CODE 6210-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 97N-0137]

Cellpro, Inc.; Premarket Approval of CEPRATE® SC Stem Cell Concentration System

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing its approval of the application by CellPro, Inc., Bothell, WA, for premarket approval, under the Federal Food, Drug, and Cosmetic Act (the act), of the CEPRATE® SC Stem Cell Concentration System (CEPRATE® SC System). FDA's Center for Biologics Evaluation and Research (CBER) notified the applicant, by letter of December 6, 1996, of the approval of the application.

DATES: Petitions for administrative review by May 27, 1997.Q02

ADDRESSES: Written requests for copies of the summary of safety and effectiveness data and petitions for administrative review to the Dockets Management Branch (HFA-305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1-23, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Keith O. Webber, Center for Biologics Evaluation and Research (HFM-594), 1401 Rockville Pike, Rockville, MD 20852-1448, 301-827-5103.

SUPPLEMENTARY INFORMATION: On January 3, 1994, CellPro, Inc., Bothell, WA 98021, submitted to CBER an application for premarket approval of the CEPRATE® SC System. The device is indicated for the processing of autologous bone marrow to obtain a cell population enriched with cells displaying the CD34 surface marker (CD34+). Such cells are intended for hematopoietic support after myeloablative chemotherapy. Infusion of CD34+ enriched cell populations results in a lower incidence of dimethyl sulfoxide infusion-associated complications compared with infusion of unselected bone marrow cells. The CEPRATE® SC System consists of an instrument and a single-use, sterile, prepackaged kit containing disposable components which includes: (1) An avidin column, (2) a precolumn, (3) a tubing set, (4) a vial of anti-CD34+ biotinylated monoclonal antibody, (5) a blood filter, and (6) wash and culture media. The CEPRATE® SC System concentrates CD34+ cells using a